-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compileriver
On June 3, according to foreign media reports, Roche’s oral spinal muscular atrophy (SMA) drug Evrysdi was too expensive to be approved by the UK drug price regulator.
NICE stated that SMA is a progressive neuromuscular disease that affects the spinal nerves that control movement.
Nevertheless, the agency recognizes that oral administration of Evrysdi makes it a better choice for some patients.
NICE currently recommends Spinraza for pre-symptomatic SMA patients or patients with type 1, 2 or 3 disease.
The agency's decision may trigger further discussion.
Reference source: Roche's oral SMA med Evrysdi turned down by UK cost watchdog—despite prior nods for Zolgensma and Spinraza
Reference source: Roche's oral SMA med Evrysdi turned down by UK cost watchdog—despite prior nods for Zolgensma and Spinraza